0001127602-20-018883.txt : 20200604
0001127602-20-018883.hdr.sgml : 20200604
20200604181839
ACCESSION NUMBER: 0001127602-20-018883
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20200602
FILED AS OF DATE: 20200604
DATE AS OF CHANGE: 20200604
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Kim Lorence H.
CENTRAL INDEX KEY: 0001643746
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-38753
FILM NUMBER: 20943982
MAIL ADDRESS:
STREET 1: C/O SERES HEALTH, INC.
STREET 2: 161 FIRST STREET
CITY: CAMBRIDGE
STATE: MA
ZIP: 02472
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Moderna, Inc.
CENTRAL INDEX KEY: 0001682852
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 813467528
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
BUSINESS PHONE: 6177146500
MAIL ADDRESS:
STREET 1: 200 TECHNOLOGY SQUARE
CITY: CAMBRIDGE
STATE: MA
ZIP: 02139
FORMER COMPANY:
FORMER CONFORMED NAME: Moderna Therapeutics, Inc.
DATE OF NAME CHANGE: 20160822
4
1
form4.xml
PRIMARY DOCUMENT
X0306
4
2020-06-02
0001682852
Moderna, Inc.
MRNA
0001643746
Kim Lorence H.
C/O MODERNA, INC.
200 TECHNOLOGY SQUARE
CAMBRIDGE
MA
02139
1
Chief Financial Officer
Common Stock
2020-06-02
4
M
0
78309
14.22
A
1280819
D
Common Stock
2020-06-02
4
M
0
66031
19.15
A
1346850
D
Common Stock
2020-06-02
4
M
0
96660
19.15
A
1443510
D
Common Stock
2020-06-02
4
S
0
241000
58.30
D
1202510
D
Stock Option (Right to Buy)
14.22
2020-06-02
4
M
0
78309
0
D
2028-02-28
Common Stock
78309
587735
D
Stock Option (Right to Buy)
19.15
2020-06-02
4
M
0
66031
0
D
2026-08-10
Common Stock
66031
578372
D
Stock Option (Right to Buy)
19.15
2020-06-02
4
M
0
96660
0
D
2026-08-10
Common Stock
96660
0
D
The reported transaction was effected pursuant to a Rule 10b5-1 trading plan adopted on March 13, 2020.
458,715 of the options will vest over 4 years (25% on February 27, 2019, then quarterly for the next 3 years), 229,358 of the options will vest over 5 years (25% on February 27, 2020, then quarterly for the next 3 years), 229,358 of the options will vest over 6 years (25% on February 27, 2021, then quarterly for the next 3 years).
This option is fully vested and exercisable.
/s/ Lori Henderson, as Attorney-in-Fact
2020-06-04